drugset / Trial / NCT02444000
gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas
Phase 3
Completed
280 enrolled
Assistance Publique - Hôpitaux de Paris
Association de Neuro-Oncologues d'Expression Francaise · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with 1p/19q-codeleted anaplastic gliomas treated with RT + PCV are at risk of neurocognitive deterioration. Treating these patients with PCV alone (could reduce the risk of neurocognitive deterioration without impairing overall survival.
Timeline
- Start
- 2015-09-22
- Primary completion
- 2022-10-11
- Completion
- 2024-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Lomustine | Small molecule | 110 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | procarbazine | Small molecule | 60 mg/m2 | Oral |